your partner that cares

Value Added Medicines

- Oromucosal Delivery
- Complex Steriles
- OSD Fixed-Dose Combinations

bluepharma
Oromucosal delivery

BlueOS® and BluEase™ are innovative and versatile platforms based on proprietary technologies for the delivery of drug substances through the oral mucosa and gastrointestinal tract.

These patient-centric technologies enable both the incorporation of New Chemical Entities and the repurposing of known drugs, including off-patent molecules.

Crossing boundaries towards patients’ needs, prescribers’ confidence and payers’ outcomes.

CONVENIENCE
Allowing patients and caregivers to succeed:
- Patients with dysphagia and difficulties to swallow, such as pediatrics and geriatrics.
- Emergency situations and non-collaborative patients.
- On-the-go solution.

ADHERENCE AND SAFETY
Giving confidence to prescribers.
- Improved convenience resulting in improved adherence.
- Potential to be less invasive as compared to existing solutions.
- Potential for improved bioavailability and fast onset of action.

SAVINGS
Improved adherence allows for better outcomes and less visits to the hospital, representing savings to payers.

Potential Applications
- Multiple Sclerosis
- Epilepsy
- Parkinson’s Disease
- Dementia
- Migraine
- Opioid Overdose
- Alcohol Use Disorder
**Oral Thin Films**

**Buccal Sprays**

**Oral Dispersible Tablet**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>VALUE PROPOSITION</th>
<th>TYPE OF FORMULATION</th>
<th>Technical POC</th>
<th>Formulation Development</th>
<th>Clinical POC</th>
<th>Scale-up</th>
</tr>
</thead>
</table>
| Multiple Sclerosis    | • Convenience of administration (pediatrics/dysphagia)  
  • Improved compliance                                                                                                                               | Oral Thin Film                  |               |                          |              | ongoing  |
| Erectile Dysfunction  | • On-the-go and discrete solution  
  • Alternative to existing solutions                                                                                                                   | Buccal spray                    |               |                          |              | ongoing  |
| Supportive care in Oncology | • Convenience of administration  
  • Adhesive protective barrier                                                                                                                      | Buccal spray                    |               |                          |              | ongoing  |
| Migraine              | • Quickly dissolves on the tongue  
  • No need to be taken with water                                                                                                                     | Oral Dispersible Tablet         |               |                          |              | ongoing  |

**OSD Fixed-Dose Combinations**

Development of advanced formulations that aim the modulation of the release profile, overcome barriers such as incompatibilities between molecules and increase of the stability, including **multi-layer tablets**, **micro tablets**, **capsule-in-capsule** and **Hot Melt Extrusion** technologies.

| Blue073               | Candesartan  
  Atorvastatin  
  Amlodipine |
|-----------------------|-------------
| Blue074               | Ramipril  
  Atorvastatin  
  Amlodipine |

- Multi-layer technology
- Cardiovascular Therapeutic Field
- Available

**MULTILAYER TECHNOLOGY**
Get more out of a single tablet

**HOT MELT EXTRUSION**
Overcoming formulation barriers
Complex Steriles

Complex Steriles offer unique advantages and solve major challenges of conventional oral or parenteral drug delivery systems.

Lipid nanoparticles (LNP)

Bluepharma has more than 25 years of accumulated experience in lipid-based formulations (unilamellar liposomes, multivesicular liposomes, targeted and pH sensitive liposomes).

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>VALUE PROPOSITION</th>
<th>TYPE OF FORMULATION</th>
<th>Technical POC</th>
<th>Formulation Development</th>
<th>Non-clinical POC</th>
<th>Clinical POC</th>
<th>Scale-up</th>
</tr>
</thead>
</table>
| Oncology Mesotheioma | • Improved SAFETY and EFFICACY  
• IP granted in major markets WW  
• Orphan Drug Designation granted by FDA and EMA (Mesotheioma) | Liposomal           |               |                         |                  |              | ongoing  |
| Rheumatoid Arthritis | • Improved SAFETY, reducing adverse events  
• Dosing Convenience by decreasing the number of administrations | Liposomal           |               |                         |                  |              | ongoing  |

Polymer-based microparticles

Bluepharma is developing an innovative LAI technology that takes advantage of a hybrid system comprising an in-situ forming hydrogel with embedded microparticles:

• High loading capacity.
• Ability to encapsulate more than one drug.
• Fine-tuning of the drug release profile.
• Minimal or inexistet burst release.

Create value through Innovation.
How? Contact us!

For business inquiries: business@bluepharma.pt
S. Martinho do Bispo · 3045-016 Coimbra · PORTUGAL
Tel. +351 239 800 300 · Fax +351 239 800 333
www.bluepharmagroup.com

Bluepharma’s facilities are EU-GMP certified and approved by US FDA (2009, 2012, 2014, 2016, 2019), SFDA (Kingdom of Saudi Arabia), ANVISA (Brazil), MFDS (Republic of Korea), Minpromtorg (Russian Federation), MOH Libya and by TMMDA (Turkey).

We are registered in Iraq, Jordan, Kurdistan, Taiwan, UAE and Vietnam.